Cosmos Health CEO Greg Siokas Acquires A Total of 647,809 Shares Worth $425,000 in Last 32 Days Via Investing.com
CHICAGO, IL / ACCESS Newswire / January 21, 2025 / Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ 🙂A diversified, directly integrated global healthcare group engaged in R&D innovation, a pharmaceutical and nutritional product owner, a manufacturer and distributor of healthcare products, and a telehealth platform operator, announced today that its CEO, Greg Siokas , has increased his stake in the Company by acquiring 647,809 common shares, valued at $425,000, in all six happening between December 20, 2024, and January 17, 2025.
As a result of this transaction, Mr. Siokas now owns 4,164,789 common shares in Cosmos Health.
Greg Siokas, CEO of Cosmos Health, said: “I am incredibly excited about our future prospects and deeply committed to supporting Cosmos, having invested more than $17 million since its inception. We are in a transition period, and I will continue to support our efforts as we advance our strategy and vision, advance our exciting projects and expand our products ours around the world.”
Information about the Recent Activities of Mr. Siokas:
Please refer to the Form 4 filing filed with the SEC and available on the SEC’s website for more information on the nature of the transactions, including information such as “Ownership Form”, “ What is being done (JO:) Date”, “Amount”, “Price”, and other relevant information about the shares acquired by Mr. Siokas.
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), founded in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The company has a portfolio of pharmaceutical and nutritional products, including Sky Premium Life ® , Mediterranation ® , bio-bebe ® , C-Sept ® and C-Scrub ® . Through its subsidiary Cana Laboratories SA, licensed under European Good Manufacturing Practices (GMP) and approved by the European Medicines Agency (EMA), it manufactures medicines, food additives, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medicines, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. In addition, the Company has established R&D partnerships targeting major health problems such as obesity, diabetes, and cancer, enhanced by smart drug repurposing technology, and focused on R&D of patented novel nutritional supplements, specialty root extracts, complex genetics, and New OTC. products. Cosmos Health also entered the telehealth space with the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding across Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, and LinkedIn and X.
Forward-Looking Statements
Except for the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. , as amended. Statements that precede, follow, or otherwise, include the words “believes,” “anticipates,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional actions such as . such as “will,” “should,” “may,” “might” and “could”, are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially affect the matters discussed herein for various reasons beyond the Company’s control, including, but not limited to, the Company’s ability to obtain sufficient funds to start its operations. business plan, the impact of the COVID-19 pandemic and the war in Ukraine, on the Company’s business, operations and overall economy, and the Company’s ability to successfully develop and commercialize its proprietary products. and technology. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results may differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s filings with the SEC, which are available on the SEC’s website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contacts:
BDG Communications
cosm@bdgcommunications.com
+44 207 0971 653
SOURCE: Cosmos Health Inc.
View the original press release on ACCESS Newswire
